New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies

Disease relapse caused by drug resistance still represents a major clinical hurdle in cancer treatments. Tumor cells may take advantage of different intracellular and genetic systems attenuating the drug effects. Resistant cells or minimal residual disease (MRD) cells have strong clinical relevance,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giulia Mitola, Paolo Falvo, Francesco Bertolini
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	tumor resistance in vitro and in vivo studies preclinical studies Science Q
Acceso en línea:	https://doaj.org/article/d75c0a279a704ce8824a27bc2c754cda
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d75c0a279a704ce8824a27bc2c754cda
record_format	dspace
spelling	oai:doaj.org-article:d75c0a279a704ce8824a27bc2c754cda2021-11-25T18:10:32ZNew Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies10.3390/life111111312075-1729https://doaj.org/article/d75c0a279a704ce8824a27bc2c754cda2021-10-01T00:00:00Zhttps://www.mdpi.com/2075-1729/11/11/1131https://doaj.org/toc/2075-1729Disease relapse caused by drug resistance still represents a major clinical hurdle in cancer treatments. Tumor cells may take advantage of different intracellular and genetic systems attenuating the drug effects. Resistant cells or minimal residual disease (MRD) cells have strong clinical relevance, as they might give rise to secondary tumors when the therapy is concluded. Thus, MRDs are crucial therapeutic targets in order to prevent tumor relapse. Therefore, several groups aim at understanding how MRDs are orginated, characterizing their molecular features, and eradicating them. In this review, we will describe MRD from a genetic, evolutionary, and molecular point of view. Moreover, we will focus on the new in vitro, in vivo, preclinical, and clinical studies that aim at eradicating tumor resistance.Giulia MitolaPaolo FalvoFrancesco BertoliniMDPI AGarticletumor resistancein vitro and in vivo studiespreclinical studiesScienceQENLife, Vol 11, Iss 1131, p 1131 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	tumor resistance in vitro and in vivo studies preclinical studies Science Q
spellingShingle	tumor resistance in vitro and in vivo studies preclinical studies Science Q Giulia Mitola Paolo Falvo Francesco Bertolini New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies
description	Disease relapse caused by drug resistance still represents a major clinical hurdle in cancer treatments. Tumor cells may take advantage of different intracellular and genetic systems attenuating the drug effects. Resistant cells or minimal residual disease (MRD) cells have strong clinical relevance, as they might give rise to secondary tumors when the therapy is concluded. Thus, MRDs are crucial therapeutic targets in order to prevent tumor relapse. Therefore, several groups aim at understanding how MRDs are orginated, characterizing their molecular features, and eradicating them. In this review, we will describe MRD from a genetic, evolutionary, and molecular point of view. Moreover, we will focus on the new in vitro, in vivo, preclinical, and clinical studies that aim at eradicating tumor resistance.
format	article
author	Giulia Mitola Paolo Falvo Francesco Bertolini
author_facet	Giulia Mitola Paolo Falvo Francesco Bertolini
author_sort	Giulia Mitola
title	New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies
title_short	New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies
title_full	New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies
title_fullStr	New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies
title_full_unstemmed	New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies
title_sort	new insight to overcome tumor resistance: an overview from cellular to clinical therapies
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d75c0a279a704ce8824a27bc2c754cda
work_keys_str_mv	AT giuliamitola newinsighttoovercometumorresistanceanoverviewfromcellulartoclinicaltherapies AT paolofalvo newinsighttoovercometumorresistanceanoverviewfromcellulartoclinicaltherapies AT francescobertolini newinsighttoovercometumorresistanceanoverviewfromcellulartoclinicaltherapies
_version_	1718411528226471936

New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies

Ejemplares similares